Land: Bretland
Tungumál: enska
Heimild: VMD (Veterinary Medicines Directorate)
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
MSD Animal Health UK Limited
QI06AD04
Feline calicivirus, Feline panleukopenia virus, Feline viral rhinotracheitis virus
Lyophilisate and solvent for suspension for injection
POM-V - Prescription Only Medicine – Veterinarian
Cats
Live Viral Vaccine
Authorized
2007-05-01
Revised: February 2023 AN: 00706/2022 Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection for cats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose (1 ml) of reconstituted vaccine contains: ACTIVE SUBSTANCES: Live attenuated feline calicivirus, strain F9: 10 4.6 PFU 1 ; Live attenuated feline rhinotracheitis virus, strain G2620A: 10 5.2 PFU 1 ; Live attenuated feline panleucopenia virus, strain MW-1: 10 4.3 CCID 50 2 . 1 PFU: Plaque-Forming Units 2 CCID 50 : Cell Culture Infectious Dose 50% EXCIPIENTS: QUALITATIVE COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS_ _ Lyophilisate: Disodium phosphate dihydrate Hydrolysed gelatin Pancreatic digest of casein Sorbitol Solvent: Disodium phosphate dihydrate Potassium dihydrogen phosphate Water for injections Lyophilisate: off-white pellet. Solvent: clear colourless solution. 3. CLINICAL INFORMATION 3.1 TARGET SPECIES Cats. 3.2 INDICATIONS FOR USE FOR EACH TARGET SPECIES Active immunisation of cats: - to reduce the clinical signs caused by infection with feline calicivirus (FCV) and feline rhinotracheitis virus (FVR), - to prevent the clinical signs, leucopenia and virus excretion caused by infection with feline panleucopenia virus (FPLV). Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks. Revised: February 2023 AN: 00706/2022 Page 2 of 6 Duration of immunity for FCV and FVR: 1 year; for FPLV: 3 years. 3.3 CONTRAINDICATIONS See section 3.7. 3.4 SPECIAL WARNINGS Vaccinate healthy animals only. Maternal antibodies, which may persist up to the age of 9 –12 weeks, can have a negative influence on the efficacy of vaccination. In the presence of maternal antibodies, vaccination may not completely prevent the clinical signs, leucopenia and virus excretion following an FPLV infection. In such cases where a relatively high level of maternally derived antibodies is expected, the vaccination schedule should be planned accordingly. 3.5 SPEC Lestu allt skjalið